Informations:
Erreur:
ID
12971
Description
A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT00270400
Lien
https://clinicaltrials.gov/show/NCT00270400
Mots-clés
Versions (1)
- 08/01/2016 08/01/2016 -
Détendeur de droits
CC BY-NC 3.0
Téléchargé le
8 janvier 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Heart Failure, Congestive NCT00270400
Eligibility Heart Failure, Congestive NCT00270400
- StudyEvent: Eligibility
Similar models
Eligibility Heart Failure, Congestive NCT00270400
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
congestive heart failure
Item
history of nyha (new york heart association) class iii or iv congestive heart failure (chf)
boolean
C1275491 (UMLS CUI [1])
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
Item
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
boolean
C0018802 (UMLS CUI [1])
C0012963 (UMLS CUI [2])
C0012798 (UMLS CUI [3])
C0012963 (UMLS CUI [2])
C0012798 (UMLS CUI [3])
oral antiarrhythmic medications
Item
receiving stable doses of oral antiarrhythmic medications (medications that help regulate irregular heart beats) for at least the 48 hours before starting study drug, or receiving no antiarrhythmic medications.
boolean
C0003195 (UMLS CUI [1])
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
Item
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
boolean
C1980011 (UMLS CUI [1])
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
Item
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
boolean
C0005823 (UMLS CUI [1])
C0036980 (UMLS CUI [2])
C0948268 (UMLS CUI [3])
C0036980 (UMLS CUI [2])
C0948268 (UMLS CUI [3])
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
Item
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
boolean
C1980011 (UMLS CUI [1])
C0013030 (UMLS CUI [2])
C0013030 (UMLS CUI [2])
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
Item
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
boolean
C0013030 (UMLS CUI [1])
C0012963 (UMLS CUI [2])
C0128513 (UMLS CUI [3])
C0028193 (UMLS CUI [4])
C0017887 (UMLS CUI [5])
C0012963 (UMLS CUI [2])
C0128513 (UMLS CUI [3])
C0028193 (UMLS CUI [4])
C0017887 (UMLS CUI [5])
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
Item
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
boolean
C0003195 (UMLS CUI [1])